TP

TP is a preclinical-stage small molecule drug candidate developed by JW Pharmaceutical that functions as an inhibitor of the Wnt signaling pathway. It is being investigated for its therapeutic potential in treating a range of immunological diseases as well as cardiovascular and metabolic disorders. The Wnt signaling pathway is a critical regulator of various cellular processes, including cell growth, differentiation, and inflammation; its dysregulation is implicated in the pathogenesis of many chronic diseases. TP is part of JW Pharmaceutical's broader effort to leverage its proprietary Wnt modulator platform to develop targeted therapies for conditions with high unmet medical needs.